News & Updates
Filter by Specialty:

5α-reductase inhibitor treatment implicated in dementia
Men who are receiving treatment with 5α-reductase inhibitors (5-ARIs) are at increased risk of dementia in the immediate period after initiating treatment, a study has shown. Of note, both finasteride and dutasteride are associated with depression, but neither of them is linked to suicide.
5α-reductase inhibitor treatment implicated in dementia
05 Jan 2023
Edoxaban prevents thromboembolism in children with cardiac disease
Edoxaban may be used as an alternative treatment for thromboembolism (TE) prevention in children with cardiac disease showing low rates of clinically relevant bleeding and TE, suggests a study. Some of its advantages include once-daily dosing and infrequent monitoring requirement.
Edoxaban prevents thromboembolism in children with cardiac disease
04 Jan 2023
Metformin medication not protective against age-related macular degeneration
Treatment with metformin, along with lifestyle changes, initiated for the prevention of diabetes does not appear to reduce the risk of age-related macular degeneration, a study has found.
Metformin medication not protective against age-related macular degeneration
02 Jan 2023
Procalcitonin-based algorithm reduces unnecessary antibiotic use in acute pancreatitis
A procalcitonin-guided algorithm could reduce the unnecessary use of antibiotics in patients with acute pancreatitis, according to results of the PROCAP trial.
Procalcitonin-based algorithm reduces unnecessary antibiotic use in acute pancreatitis
01 Jan 2023
Parkinson’s, T2D drug affords cardioprotection in youth with T1D
Bromocriptine quick release, a medication used for Parkinson’s disease and type 2 diabetes (T2D), appears to confer cardiovascular benefits such as lower blood pressure (BP) and reduced aortic stiffness in teenagers with type 1 diabetes (T1D), according to data from the BCQR-T1D study.
Parkinson’s, T2D drug affords cardioprotection in youth with T1D
31 Dec 2022
Semaglutide triumphs as an anti-obesity treatment for adolescents
Adding a once-weekly dose of semaglutide to lifestyle intervention successfully reduced body mass index (BMI) in adolescents with obesity, according to results of the phase IIIa STEP TEENS trial.